Knowledge (XXG)

Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Long COVID Neurological and psychological symptoms Post-exertional malaise Society Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health Migration Military Notable deaths Other health issues Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Politics Diplomacy Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

COVID-19 vaccination in Thailand is an ongoing mass immunization in response to the ongoing pandemic in the country.

In November 2020, the authorities ordered 26 million doses of vaccine from AstraZeneca, which reported 70% overall efficacy. It requires 2 doses of vaccine per person, so the quantity ordered would only cover 13 million people. Prayut cabinet later approved budget for ordering 35 million additional doses in January 2021. Siam Bioscience, a company owned by King Vajiralongkorn, will received technological transfer for co-investment. The authorities also imported 2 million doses of vaccine from Sinovac, a Chinese company which Thai conglomerate Charoen Pokphand invested in, during February to April 2021.

Likewise, the Thai government also stepped up its attempt to produce its homegrown vaccines amidst criticism, with "ChulaCov19" and set to begin trials in May 2021. Phase I testing of the NDV-HXP-S vaccine began at Mahidol University in March 2021.

In July 2021, the National Vaccine Institute apologized for slow vaccine deployment. Meanwhile, the government's prior commitment to secure 61 million doses of AstraZeneca vaccine became doubted after a leaked document showed that the company would deliver no more than 60 percent of the number planned per month. A virology advisor also endorsed an untested plan to mix AstraZeneca and Sinovac vaccines. There was already a report of death from the practice, but health professionals said they have to rule out other causes first.

Free Vaccines which are provided under the policies of the Ministry of Public Health.

Vaccine name	Doses ordered (excluding donation)	Doses arrived (including donation)	Approval (EUA)	First Arrival	Deployment	Ref
Oxford–AstraZeneca	61 million	25.5 million	20 January 2021	24 February 2021	28 February 2021
CoronaVac	31.1 million	26.52 million	22 January 2021	24 February 2021	28 February 2021
Janssen	5 million	unknown	25 March 2021	Late June	26 July 2021
Pfizer–BioNTech	30 million	3.5 million	24 June 2021	30 July 2021	5 Aug 2021

Vaccines that are not in the policies of the Ministry of Public Health. Orders are made through government organizations but the cost of vaccination will not be supported by the government. However, people who get vaccinated by these vaccines are still counted in the national vaccination programme.

Vaccine name	Distributor	Doses planned or ordered	Doses arrived	Approval (EUA)	First Arrival	Deployment	Ref
Moderna	Government Pharmaceutical Organization	5 million	0.5602 million	13 May 2021	1 Nov 2021	5 Nov 2021
	Chulabhorn Royal Academy	8 million	Not yet	13 May 2021	Not yet	Not yet
Sinopharm BIBP (BBIBP-CorV)	Chulabhorn Royal Academy	15 million	15 million	28 May 2021	20 June 2021	25 June 2021

• Sputnik V
• Covaxin

Vaccination procedures used in Thailand.

First Dose	Second Dose	Third Dose	Fourth Dose	Dose Interval
CoronaVac or Sinopharm BIBP	CoronaVac or Sinopharm BIBP	Oxford–AstraZeneca or Pfizer–BioNTech or Moderna	Oxford–AstraZeneca or Pfizer–BioNTech or Moderna	2–4 weeks (2nd) 4 weeks (3rd) 3 month (4th)
CoronaVac or Sinopharm BIBP	Oxford–AstraZeneca	Oxford–AstraZeneca or Pfizer–BioNTech or Moderna	Oxford–AstraZeneca or Pfizer–BioNTech or Moderna	3–4 weeks (2nd) 3 month (3rd and 4th)
CoronaVac or Sinopharm BIBP	Pfizer–BioNTech or Moderna	Pfizer–BioNTech or Moderna	Pfizer–BioNTech or Moderna	3–4 weeks (2nd) 6 month (3rd) 3 month (4th)
Oxford–AstraZeneca	Oxford–AstraZeneca	Pfizer–BioNTech or Moderna	Pfizer–BioNTech or Moderna	10–16 weeks (2nd) 3 month (3rd and 4th)
Oxford–AstraZeneca	Pfizer–BioNTech or Moderna	Pfizer–BioNTech or Moderna	Pfizer–BioNTech or Moderna	4–12 weeks (2nd) 6 month (3rd) 3 month (4th)
Pfizer–BioNTech or Moderna	Pfizer–BioNTech or Moderna	Pfizer–BioNTech or Moderna	Pfizer–BioNTech or Moderna	4–12 weeks (2nd) 6 month (3rd) 3 month (4th)

• MOPH suspended the procedures of the first two doses of Sinovac vaccine on 12 July 2021 due to inefficient immunization against Delta variant. People who received the Sinovac vaccine for the first dose and had an appointment date for second dose after suspension, the second doses will be switched to other vaccines automatically.
• MOPH suspended the procedures of the first two doses of AstraZeneca on 11 September 2021 due to long dose interval process which takes time for creating immunization. People who received the first dose of AstraZeneca vaccine before the suspension will continue to receive the same AstraZeneca vaccine for second dose. However, People who haven't received the first dose before the suspension will have to start with other procedures instead.
• Excluding the procedure of Jannsen vaccine which is currently imported and managed by the Embassy of France in Thailand under the approval of MOPH, only French nationals living in Thailand are eligible to receive this vaccine for now.

Vaccine	Type (technology)	Progress
NDV-HXP-S (HXP-GPOVac) Mahidol University, University of Texas at Austin,	Newcastle disease virus (NDV) viral vector (expressing the spike protein of SARS-CoV-2, with or without the adjuvant CpG 1018) or Inactivated	Phase I–II (460) Randomized, placebo-controlled, observer-blind. Mar 2021 – May 2022; Thailand
ChulaCov19 Chulalongkorn University	RNA	Phase I–II (96) Dose-finding Study. Jan–Mar 2021, Thailand
Baiya SARS-CoV-2 Vax 1 Baiya Phytopharm Co Ltd.	Plant-based Subunit (RBD-Fc + adjuvant)	Phase I (96) Randomized, open-label, dose-finding. Sep–Dec 2021, Thailand
COVIGEN Bionet Asia, Technovalia, University of Sydney	DNA	Phase I (150) Double-blind, dose-ranging, randomised, placebo-controlled. Feb 2021 – Jun 2022, Australia, Thailand

• COVID-19 vaccination by country
• COVID-19 pandemic in Thailand
• COVID-19 pandemic by country